Publication | Open Access
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
100
Citations
16
References
2019
Year
( ClinicalTrials.gov Identifier: NCT02028442 ). Trial registration date: 07 January 2014 - Retrospectively registered.
| Year | Citations | |
|---|---|---|
Page 1
Page 1